17th Jun 2024 07:23
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.
Current stock price: 12,510.00 pence
12-month change: up 7.4%
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca